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ABSTRACT 
BACKGROUND: 
 Critically ill patients in the Medical Intensive Care Unit (MICU) require 
multiple medications, often administered as continuous intravenous infusions. 
Two or more medications that are administered via Y-site connector mix in the 
lumen of the tubing prior to being infused into the patient. However, not all 
medications can be physically mixed together. The potential complications of 
co-administration of incompatible medications include precipitation, central 
venous catheter occlusion requiring additional venous access, reduced 
potency of medication, therapeutic failure and local and systemic 
inflammatory reactions. Various factors such as solvents, diluents, infusion 
fluids, pH of each drug, duration of stability and concentration of the selected 
critical care drugs play a major role in determining the compatibility of 
intravenous drug infusions at the Y-junction. 
OBJECTIVES: 
 To study the influence of polyvalent ions in the co-infused drug 
solutions and acid-base reactions between the continuously infused 
drug solution and Y-site administered drug on the physicochemical 
compatibility of various critical care drugs used in the Medical Intensive 
Care Unit.  
 To identify the most frequent and clinically significant incompatibilities 
of continuous IV infusions of the selected critical care drugs with Y-site 
administered drugs in the MICU settings 
STUDY DESIGN:  
 Prospective observational study 
STUDY DURATION:  
 10 months (from November 2015 to August 2016). 
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SETTING:  
 Medical Intensive Care (MICU) unit of a 750 bedded multispecialty 
tertiary care teaching hospital. 
PATIENTS:  
        Patients admitted to the Medical Intensive Care Unit, receiving Y- 
administration of drugs along with continuous intravenous infusions are 
included.  
METHOD:  
Compatibility of the selected critical care drugs when given as 
continuous intravenous infusions are analyzed against the Y-site administered 
drugs using the 2-dimensional compatibility chart. A 2-dimensional 
compatibility chart is prepared indicating the compatibility of selected critical 
care drug infusions with Y-site administered drugs commonly used in the 
Medical Intensive Care Unit is prepared 
RESULTS 
         Five hundred and fifty four (81.23%) of the prescribed medications were 
administered intravenously, of these two hundred and sixty two (38.4%) drugs 
were given as continuous intravenous infusions while two hundred and ninety 
two drugs were given through Y-Site. Of the 600 drug-drug combinations or 
drug-diluent combinations evaluated, two hundred and two combinations 
(33.66%) were found to be compatible while 17 (2.83%) combinations were 
incompatible. The compatibility information of 354 (59%) combinations are not 
reported in the literature and 27 combinations were reported as caution 
(4.5%). Most of the incompatibilities were due to differing pH values of the 
drug pairs or drug and diluents. Ringer lactate and ceftriaxone is the only one 
drug –diluent combination and it is due to the presence of polyvalent cation 
(Ca++) in the diluents. A 2-dimensional compatibility chart prepared and this 
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indicating the compatibility of selected continuous intravenous infusions with 
Y-site administered drugs commonly used in the MICU. 
CONCLUSION: 
 The present study helps in the identification of the factors causing 
incompatibility of continuous intravenous infusions and Y-site administered 
drugs in the Medical Intensive Care Unit. The proposed study  reviewed the 
compatibility of continuous intravenous infusions of certain selected critical 
care drugs   against Y-site administered drugs with a view to improving the 
safety of multidrug therapy in the Medical Intensive Care Unit. The study also 
lead to the development of a two dimensional Y-site compatibility chart for 
commonly used critical care drugs in the Medical Intensive Care unit.  
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INTRODUCTION 
INTRAVENOUS THERAPY 
Intravenous (IV) delivery is extensively used for many reasons; it has 
rapid onset, high bioavailability, rapid clearance once stopped, and therefore 
is suitable for dose titration and maintenance of effect. Frequently the number 
of IV medication is more than number of venous access lumens for these 
patients. Consequently, co- administration of more than one medication in the 
same container, or same line, is inevitable. Evidence shows adding of 
additional lumens increases opportunities for infection, and multi lumen CVC’s 
increase the risk of catheter related blood stream infection.. A larger number 
of medications will increase the incompatibility risk geometrically. However, 
this complex situation is poorly understood by health staff1. In modern medical 
practice, up to 80% of hospitalized patients receive intravenous therapy at 
some point during their admission. Medication, fluids, nutrition, and blood 
products can all be given via the intravenous route, which can be either 
peripheral or central. Although common, these practices are not devoid of 
complications, which may lead to mortality and morbidity, increased duration 
of hospital stay, and significant costs. 
Peripheral Venous Cannulation: Peripheral venous cannulation is the 
commonest method used for intravenous therapy. There are numerous well 
recognised indications and contraindications for peripheral venous 
cannulation, but, despite these, there is no doubt that many intravenous lines 
are inserted unnecessarily. A French study also found that 28% of peripheral 
cannulae inserted in an emergency department were ‘‘unjustified’’. Indications 
for peripheral venous cannulation include intravenous fluids, limited parenteral 
nutrition, blood and blood products, drug administration (continuous or 
intermittent), prophylactic use before procedures, prophylactic use in unstable 
patients.  
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Central Venous Cannulation: Central venous cannulation is 
increasingly used not only in intensive care and high dependency units but 
also on general medical and surgical wards. Many problems can occur with 
the insertion of a central venous catheter, including arterial puncture, puncture 
of a lung leading to a pneumothorax, and perforation of the right atrium or 
pulmonary artery. Appropriate training and experience is essential in avoiding 
these complications, especially since the majority of central venous catheters 
are inserted by doctors in training. This has been recognised by the National 
Institute for Clinical Excellence in the UK, which has published guidelines that 
recommend two dimensional ultrasound guidance as the preferred method for 
cannulation of the internal jugular vein. The guidelines also stipulate that 
clinicians undertaking this procedure should receive appropriate training to 
achieve competence since the technique is operator dependent with a long 
learning curve.2  
ADMINISTRATION TECHNIQUES IN INTRAVENOUS DRUG THERAPY 
Drugs are also frequently administered by the intravenous route, either 
as bolus injections or by infusion. The indications for the intravenous 
administration of drugs can be summarised as follows: 
 If the patient has a serious disease, the administration of a drug 
intravenously may have advantages over oral drug administration in 
terms of reducing mortality. This is perceived to be the case in patients 
with life threatening bacterial infections. Although the use of 
intravenous antibiotics may often be indicated in patients with serious 
infections, it is common practice in hospitals to start intravenous 
antibiotics irrespective of the severity of the infection. Oral antibiotics in 
most of the patients admitted to hospital with bacterial infections are 
just as effective as intravenous antibiotics and have the added 
advantages of ease of administration, reduce labour and administration 
costs, and reduced hospital stay. 
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 The drug may have limited oral bioavailability or only be available in an 
intravenous preparation; for example, amino glycoside antibiotics are 
polycations and highly polar and thus will not be absorbed via the 
gastrointestinal tract; therefore, they have to be administered 
parenterally 
1. Continous Intravenous Infusion: High concentration drugs are used 
by continuous infusion because of facilitated monitoring (sampling time 
is not critical after the first loading dose, making interpretation of blood 
levels and pharmacokinetic calculations easier), potential decreased 
toxicity, easier nursing and the possibility of centralized preparation of 
ready-to-use solutions. To safely implement this mode of administration 
in a routine hospital setting it is, however, essential to ensure that drug 
remains stable over the whole process and that incompatibilities with 
other medications co-administered by the intravenous route are 
avoided3 
2. Intermittent Intravenous Infusion: Intravenous intermittent infusion is 
an infusion of a volume of fluid/medication over a set period of time at 
prescribed intervals and then stopped until the next dose is required. 
An intermittent IV medication may be called a piggyback medication, a 
secondary medication, or a mini bag medication Intravenous 
medications may be given in small volumes of sterile IV solution (25 
to 250 ml) and infused over a desired amount of time (given for 30 
minutes every 4 hours) or as a single dose. Many medications must be 
given slowly to prevent harm to the patient, and this method of 
administration reduces the risk of rapid infusion. A piggyback 
medication is given through an established IV line that is kept patent by 
a continuous IV solution or by flushing a short venous access device 
(saline lock). Always check the Parenteral Drug Therapy Manual PDTM 
to ensure the correct guidelines are followed for each specific 
medication given in IV solution. The PDTM provides guidelines on how 
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to mix the IV medication, the amount and type of solution, and the rate 
of infusion4  
An intermittent medication may be administered by gravity or on an 
electronic infusion device (EID), also known as an infusion (IV) pump. Many 
piggyback IV medications must be on an IV pump, which requires 
programming and specialized training to prevent medication errors. The IV 
infusion pumps provide hard- and soft-dose limits and safety practice 
guidelines to aid in safe medication administration5. IV medications may also 
be given by gravity infusion, in which case the health care provider must 
calculate the infusion rate for drops per minute. The best practice for 
piggyback infusions is to use an IV infusion pump. 
 
 
 
 
 
 
 
Figure showing Secondary medication (upper IV mini bag) set up with primary 
infusion set (lower IV Bag) 
3. Bolus Injection: The I.V. bolus injection method allows rapid drug 
administration. It can be used in an emergency to provide an immediate 
drug effect. It can also be used to administer drugs that can’t be given I.M., 
to achieve peak drug levels in the bloodstream, and to deliver drugs that 
can’t be diluted, such as diazepam, digoxin, and phenytoin. The term 
bolus usually refers to the concentration or amount of a drug. I.V. push is a 
technique for rapid I.V. injection. Bolus doses of medication may be 
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injected directly into a vein, through an existing I.V. line, or through an 
implanted vascular access port(VAP). The medication administered by 
these methods usually takes effect rapidly, so the patient must be 
monitored for an adverse reaction, such as cardiac arrhythmia and 
anaphylaxis. I.V. bolus injections are contraindicated when rapid drug 
administration could cause life-threatening complications. For certain 
drugs, the safe rate of injection is specified by the manufacturer. Some 
facilities permit only specially trained nurses (such as emergency 
department, critical care, and chemotherapy nurses) to give bolus 
injections.  
                                  
                                                       
  
 
 
Figure showing iv bolus administration of drug 
 
  
 
 
 
 
 
Figure showing  Y-Site Administration of drugs 
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Critically ill hospitalized patients are often in need of many intravenous 
drugs, and a frequent problem is the lack of sufficient number of access sites 
or available lumen in multi-lumen catheters, to administer each product 
separately If a patient receives a continuous infusion of total parenteral 
nutrition (TPN), the infusion should be stopped and the line flushed before 
administration of other drugs in the same line However, frequent stops may 
lead to under-nutrition, and the repeated flushing may be problematic with 
regard to the patient’s fluid balance . In this situation it might be beneficial to 
co-administer drugs and TPN through a Y-site connector.6  
 INTRAVENOUS ADMIXTURES 
Intravenous admixtures are the preparations consist of one or more 
sterile drug products added to an IV fluid, generally Sodium Chloride Solution 
(0.9% Nacl) or Dextrose alone or in combination. IV admixtures are used for 
drugs intended for continuous infusion. Drugs that may cause irritation or 
toxicity when given as a rapid direct IV injection are also prepared as IV 
admixtures. These parental drug solutions are commonly mixed in the same 
infusion bag, at the Y-site junction where two or more IV lines meet and in the 
same syringe. Intravenous Incompatibilities occur when two are more drugs 
are administered through a single intravenous line or given in a single 
solution, resulting in an undesirable reaction. The number of IV medications 
continues to expand and the need to administer different IV drug 
combinations are increasing day by day. In general nursing staff prepare and 
administer intravenous drugs prescribed by Doctors. Due to increased 
number of drug combinations, the knowledge regarding intravenous drugs is 
limited7. 
INCOMPATIBILITIES IN INTENSIVE CARE UNIT 
Incompatibility describes preventable or reversible precipitation or 
insolubility. An incompatibility reaction occurs inside a fluid container or 
infusion line and is usually visible. Visible precipitation (and all precipitation 
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that may be clinically significant is not visible) has been described as physical 
incompatibility. However, precipitates are physical products of intermolecular 
and interionic forces .8Mixing solutions of parenteral drugs is generally not 
recommended because of the potential for incompatibility and consequent 
loss of activity of one or both drugs. However, in some circumstances there 
may be compelling reasons for mixing two or more parenteral drug solutions 
in the same infusion bag, in the same syringe or at a Y-site junction where two 
or more intravenous lines meet. The decision to mix drugs should not be 
made without knowledge of their compatibility. If intravenous drugs are not 
mixed but are given consecutively, the infusion line should be flushed through 
with compatible fluid between each administration.9 
Incompatibilities became an issue of concern, especially in intensive 
care units (ICUs), because of the large fraction of parenteral drug 
applications, the need for constant drug concentrations (e.g., vasoactive 
support), and the limited number of independent i.v. lines in critically ill 
patients.12-15 Compatibility is not certain for drug combinations in which the 
compatibility is unknown or ambiguous for up to 45% of coinfusions in an 
ICU10. Physicochemical incompatibilities between intravenous drugs are a 
recurrent problem in hospitals, mainly in intensive care units (ICUs). Critically 
ill patients often require multiple infusions of several drugs, which are 
administered simultaneously by the same intravenous line of a multi lumen 
catheter.11. Assessing their mutual physicochemical compatibility is therefore 
important to avoid precipitate formation or chemical inactivation of one or 
more drugs.12In the intensive care medicine, 25% of medication errors are 
highly significant clinical incompatibilities leading to loss of activity or 
increased microparticle load and posing severe risks for patients. Tissot et al 
stated that more than 63% of errors were significant and 26% even life 
threatening.11 Mixing incompatible drugs is considered a serious medication 
error that could lead to therapeutic failure, microembolisms or even toxicity. 
Some authors found a high incidence of medication errors related to drug 
administration in intensive care units (ICUs). Taxis and Barber observed a 
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48% error rate in a German hospital, with 25% of these errors due to the co-
administration of potentially incompatible drugs Carmen13.Although this issue 
represents a major problem, information about drug incompatibilities under 
clinical conditions is still lacking. In ICU wards, it is usual practice to 
administer analgesics and sedatives to a patient via a single port of entry. It is 
thus important to know whether these drugs are physicochemically compatible 
or not.11  
 TYPES OF INCOMPATABILITIES 
1. Physical Incompatibilities: Physical reactions of drugs usually 
refer to either phase separation or precipitation (e.g. after the dilution of 
alcoholic solutions) due to a change of the relation between ionization and 
nonionization and solubility8. The alteration may result in synergism, 
antagonism or new effects. 
The pH-value, Pka and the buffer capacity of the IV solutions and the drugs 
used are major factors responsible for physical interactions 8.The situation in 
an infusion regimen is specific to the combination of drugs and solution used. 
Usually, the drug has the greatest influence and therefore defines the pH-
value of the solution infused. Many drugs are weak bases, present as the 
water soluble salts of the corresponding acids. Changes in pH-value in the 
infusion tubing, e.g. from simultaneous addition of another drug, may release 
the bases from their salts. Because of the low aqueous solubility of such 
bases, particles may precipitate. The process of precipitation is influenced by 
the relative quantity of the drugs added, as well as their buffering capacity. 
These pH-dependent precipitation reactions are usually very rapid and can be 
identified within a few centi meters in the infusion tubing system. They can 
visibly be observed as crystals, haziness or turbidity.8Precipitations based on 
drug incompatibilities are responsible for the most common particle formation 
seen in complex ICU infusion lines. Further invisible physical incompatibilities 
are reactions between drugs and plastic materials (adsorption effects). This 
leads to the drugs becoming immobilized at the inner surface of infusion 
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containers or infusion lines and so lowers the concentration and drastically 
decreases the quantity of the drug administered to a patient14  
2. Chemical Incompatibility: A chemical incompatibility means that 
the drug is chemically degraded, due to oxidation, reduction, hydrolysis, or 
decomposition. Chemical reactions can manifest themselves through turbidity, 
precipitation and color changes. 
3. Therapeutic Incompatibility: Therapeutic Incompatibility may be as 
a result of prescribing certain drugs to a patient with the intention to produce a 
specific degree of pharmacological action, but the nature or intensity of the 
action produced is different from that intended by the prescriber. This occurs 
either due to error in dosage form, wrong dose or dosage form, contra-
indicated drugs or synergistic and antagonist drugs 
 MECHANISMS OF INCOMPATIBILITY 
Incompatibility problems are more likely to arise when small 
concentrated volumes are mixed in a syringe rather than in the larger volume 
of an infusion bag. This is because of higher mutual drug concentrations and 
potentially greater pH changes in the more concentrated solution. The 
absence of any visible change to a solution upon mixing does not 
automatically exclude degradation of either or both components. 
Drugs that precipitate upon dilution: Precipitation of a drug from its 
concentrated injection solution when it is diluted with water or saline is 
counter-intuitive. However, a small number of injection solutions are 
formulated in non-aqueous solvents to allow dissolution of a poorly water 
soluble substance in a small volume. In these formulations, dilution of the 
non-aqueous injection vehicle with water or saline may precipitate the drug. 
The problem is frequently observed when diazepam injection is diluted. 
Diazepam is very poorly water soluble so it is formulated as an injection 
solution in a vehicle comprising 50% propylene glycol and 10% ethanol. At 
first, dilution produces a slight turbidity which clears upon mixing, but dilution 
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beyond fourfold produces an opaque white precipitate which does not clear 
until substantial further dilution.9 
Precipitation of drugs due to pH change upon mixing: The water 
solubility of any drug is enhanced by ionisation of the molecule. For a drug 
molecule which acts as a proton acceptor (a Lowry-Bronsted base), ionisation 
is achieved by formulation in a low pH solution usually as a hydrochloride or 
hydrogen sulfate salt (for example, amiodarone hydrochloride or adrenaline 
acid tartrate). Conversely, for a drug molecule which can lose a proton or 
hydrogen ion (a Lowry-Bronsted acid – usually a weak organic acid), 
ionization is achieved by formulation in a high pH solution, usually as a 
sodium or potassium salt (for example, benzylpenicillin sodium). Any change 
in pH towards the other end of the pH scale will reduce the proportion of 
ionised to un-ionised drug in solution and will therefore reduce the water 
solubility of the drug. The most prominent example of a pH-related reduction 
insolubility is dilution of phenytoin sodium injection. The drug is formulated 
with non-aqueous solubilising agents and the solution is adjusted to a pH of 
12. Dilution of injectable phenytoin by adding it to an infusion bag lowers its 
pH and therefore reduces its solubility resulting in precipitation of the drug. 
Ionic reactions forming insoluble substances: The salts of 
monovalent cations, such as sodium and potassium, are generally more 
soluble than those of divalent cations, such as calcium and magnesium. 
Mixing solutions containing calcium or magnesium ions has a substantial risk 
of forming an insoluble calcium or magnesium salt. Mixing magnesium sulfate 
50% and calcium chloride 10% results in precipitation of insoluble calcium 
sulfate. The mixing of drug salts of calcium, and to a lesser extent 
magnesium, with phosphates, carbonates, bicarbonates, tartrates or sulfates 
should also be avoided. 
Evolution of gas: Addition of an acidic drug solution to a solution 
containing carbonate or bicarbonate may result in production of carbon 
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dioxide gas. However, the evolution of gas is a normal part of the 
reconstitution of some drugs, notably ceftazidime9 
 CAUSES OF INCOMPATABILITIES 
 Incompatibilities of drugs can occur between drugs and 
inappropriate IV solutions as diluents. 
 Two drugs (drug-drug incompatibility) when they are: 
-mixed together, e.g. within the same infusion line (simultaneous 
infusion) and/or IV container. 
- administered one after the other, but within the same infusion 
line. 
 drugs and adjuvants (preservative, buffer, stabilizer, solvent) 
 drugs and materials of IV containers (e.g. PVC) or medical 
devices, which can concern the nature of the material used 
and/or reactions at the inner surface (e.g. adsorption) . 
CONSEQUENCES OF INCOMPATIBILITY 
 Consequences for the patient 
 damage from toxic products 
 particulate emboli from crystallization and separation 
 tissue irritation due to major pH changes 
 therapeutic failure 
 Financial impact 
Adverse effects of drug incompatibilities extend periods of patients’ 
hospitalization and the total costs for hospitals. 
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STRATEGIES TO PREVENT INCOMPATIBILITIES 
 Dangerous incompatibilities can be prevented by: 
 a plausibility check regarding the SPC and available sources on 
compatability information, also considering the material used for 
therapy (eg iv containers,IV line,diluents) and the infusion regimen 
 Individual labeling for each drug preparation(including drug, 
concentration, patient name) 
 Consistently checking alternative modes of administration and or using 
multi-lumen catheters. 
 Separating the drug doses by time and place. This can include the 
rinsing of the infusion system with a neutral iv solution prior to the 
application of another drug15 
Furthermore, inline filters can reduce influx of particles which results 
from incompatibilities. Morever they can used to monitor physical and 
chemical incompatibilities. Inline filters are able to retain solid particles of at 
least 0.2µm 17As a consequence filter may be block. This is not a malfunction 
of the filter, but should initiate a check of the medication in order to eliminate 
any incompatibility.16 
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1) Rodríguez et al (2016)17 conducted a study on Development of a 
Compatibility Chart for Intravenous Y-Site Drug Administration in a Paediatric 
Intensive Care Unit. The objective of study is to develop a chart showing drug 
compatibility in Y-site administration for the most common drugs in a 
paediatric intensive care unit. Paediatric patients admitted to intensive care 
units are likely candidates for intravenous drug administration. These patients 
may sometimes have limited vascular access, so availability of compatibility 
charts for intravenous Y-site administration may help daily clinical practice. 
The authors concluded that compatibility chart is a highly reliable quick 
reference for health professionals working in the PICU, and it may help to 
prevent the intravenous administration of incompatible drugs through the 
same line. 
2)Staven et al (2016) 5carried out a study  development and evaluation of a 
test program for Y-site compatibility testing of total parenteral nutrition and 
intravenous drugs. The purpose of the study is to was to establish and 
evaluate a test program of methods suitable for detection of physical 
incompatibility in Y-site administration of total parenteral nutrition (TPN) and 
drugs. Dynamic light scattering, laser diffraction, light obscuration, 
turbidimetry, zeta potential, light microscopy, pH-measurements and visual 
examination methods were scrutinized to elucidate strengths and weaknesses 
for compatibility testing .Light obscuration together with turbidimetry, visual 
inspection and pH-measurements were able to capture signs of precipitations. 
The study concluded that testing of these complex blends should be based on 
a combination of several methods and accompanied by theoretical 
considerations. 
3) Miranda et al (2016) 18conducted a study on Compatibility: drugs and 
parenteral nutrition. The objective of study standardization and 
systematization of data to provide quick access to compatibility of leading 
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injectable drugs used in hospitals for parenteral nutrition. 55 injectable drugs 
analyzed individually with two types of parenteral nutrition: 2-in-1 and 3-in-
1and variables like: active ingredient, compatibility of drugs with the parenteral 
nutrition with or without lipids, and maximum drug concentration after dilution 
for the drugs compatible with parenteral nutrition are considered. The authors 
concluded that systematization of compatibility data provided quick and easy 
access, and enabled standardizing pharmacists work. 
4) Delaloye et al (2016)19 carried out a study on Screening for 
physicochemical incompatibilities of intravenous drugs in intensive care units: 
the case of monobasic potassium phosphate and furosemide. The aim is to 
study the physicochemical incompatibilities between intravenous drugs are a 
recurrent problem in hospital setting and having observed a drug precipitation 
during Y-site administration in our intensive care units. The study concluded 
that monobasic potassium phosphate is not compatible with furosemide in the 
concentration range used in our intensive care unit and should not be 
administered together in the same intravenous line 
5) Deepak et al (2015)20   studied on the evaluation of intravenous admixtures 
in tertiary care teaching hospital. There are no specific studies to identify the 
incompatibilities the commonly occur in hospitalized patients while 
administering these intravenous admixtures The main objective of the study 
was to assess the potential incompatibilities associated with intravenous 
admixtures in tertiary care teaching hospital. Data for the study was collected 
by Patient interview and Chart Review Method and included all the 
hospitalized patients form general medicine departments. The  obtained data 
will be compared with the information available in the literature, i.e., from 
incompatibility charts and by referring standard text Books on intravenous 
admixtures .The authors concluded that research work would certainly 
increase the safety in the use of IV admixtures by creating awareness among 
the  nurses about the complications of iv incompatibility problems .The study 
also found that preparation and placing of IV medication admixtures  
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compatibility charts and drug information leaflet in wards can help to reduce 
IV incompatibilities especially when there is a need to mixing drugs together. 
A daily prescription review by pharmacist could possibly prevent compatibility 
errors found on the wards. 
6)Wade et al (2015)21performed a study on Simulated Y-Site Compatibility of 
Vancomycin and Piperacillin-Tazobactam. The purpose of the study is to 
evaluate the physical compatibility of vancomycin with piperacillin-tazobactam 
during simulated Y-site administration. Vancomycin and piperacillin-
tazobactam were tested using 2 different diluents: 0.9%sodium chloride and 
5% dextrose for injection. The authors concluded that Y-site incompatibility 
was greater for the tested concentrations of piperacillintazobactam and 
vancomycin when 5% dextrose was used as the diluent versus 0.9% sodium 
chloride. 
7) Cabezas et al (2015)12 conducted a study on physicochemical compatibility 
of high concentration drugs usually Y-site administered in intensive care units. 
The objective is to study the physical compatibility of 63 binary mixtures of 
drugs usually Y-administered in intensive care units, and to evaluate the 
chemical stability of the most relevant binary mixtures. Binary mixtures were 
aseptically prepared in a 1:1 ratio. The study concluded by providing 
information about the physicochemical compatibility of ordinary mixtures, at 
high concentrations, commonly used in intensive care units and these results 
might help to improve drug safety management in the critically ill patient. 
8) Nagaraju et al (2015)76carried out a prospective observational study on 
the   assessment of intravenous admixtures incompatibilities & the incidence 
of intravenous drug administration errors .The objective is to assess the 
potential incompatibilities associated with IV admixtures & the incidence of IV 
drug administration errors in a tertiary care teaching hospital and included all 
the hospitalized patients of general medicine.  . The data for the present study 
was collected by chart review method. The study mainly focuses on 
compatibility of Drug-Solute and Drug-Drug combinations. The collected data 
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was analyzed for incompatibilities by using standard drug reference texts .The 
study concluded that   research work would certainly increases the safety in 
the use of IV admixtures by creating awareness among the health care 
professionals   about the incompatibility problems. 
9)Sullivan et al (2015)22 conducted a study on Compatibility of Cloxacillin 
Sodium with Selected Intravenous Drugs During Simulated Y-Site 
Administration. The objective of the study is to establish the compatibility of IV 
cloxacillin with 89 injectable drugs during simulated Y-site administration. 
Data regarding Y-site compatibility of intravenous (IV) cloxacillin sodium with 
other drugs are scarce and incomplete. The authors concluded that Sixty-four 
IV drugs were found to be compatible with cloxacillin via simulated Y-site, 
whereas 25 drugs were found to be incompatible with the antibiotic and  the 
light obscuration particle count test should be used to complement visual 
evaluation when samples do not precipitate immediately 
10) Machotka  et al (2014)23carried out a prospective cross sectional study 
on the incidence of intravenous drug incompatibilities in intensive care units. 
The aim of the study was to identify the real incidence of drug incompatibilities 
in intravenous lines in critically ill patients in two intensive care units. The 
study was carried out in one medical and one surgical ICU and patients 
included were receiving at least two different intravenous drugs. The study 
showed that a significant number of drug incompatibilities occur in both 
medical and surgical ICUs. The authors concluded   that the incidence of 
incompatibilities could be diminished by adhering to a few simple rules for 
medication administration following by recommendations for multiple lumen 
catheter use. 
11) Hanifah et al (2014)24studied on the topic of mapping of incompatibility 
assay and bringing method to problem in critical care. The aim of the study is 
to identify the methodology of incompatibility assay. A search was conducted 
of incompatibility studies through International Pharmaceutical Abstract (IPA). 
The study used both in vivo and in vitro method .In vivo method compatibility 
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in the mixture of diluted product, and also in the blood were studied .In vitro 
method, study used static and dynamic method .The study concluded that a 
standardized procedure is meaningful for general judgement for 
incompatibility and particularly in critical care, setting up an evaluation 
procedure that mimics as closely as possible real practice within the clinical 
area should be undertaken to validate practice. 
12)Raverdy et al (2013) 3performed a study on Stability and compatibility of 
vancomycin for administration by continuous infusion. The background of the 
study is that vancomycin is increasingly used by continuous infusion, but few 
specific data are available about stability under practical conditions of 
preparation and use, and compatibility with other intravenous drugs commonly 
used in the routine hospital setting. The study concluded that centralized 
preparation of vancomycin and its use by continuous infusion in wards is safe 
concerning stability, but careful attention must be paid to incompatibilities. 
13) Delaloye et al ( 2013)25  performed a study on in vitro compatibility of 
various cardioactive drugs during simulated Y-site administration. The aim of 
the study to evaluate the physicochemical compatibility of five common 
associations of cardioactive drugs: dopamine (DA)–norepinephrine (NE); 
dobutamine (DU)–NE; amiodarone (AM)–DU–NE; DU–sodium nitroprusside 
(NI)±sodium thiosulfate (THIO); and. Their compatibility was verified by visual 
inspection of the different mixtures in glass tubes and by chemical assays and 
pH determination of the mixtures collected during in vitro simulated Y-site 
administration. The study concluded that when combined, the cardioactive 
amines were stable over 24 h. AM was compatible with DU and NE, but with a 
latency period owing to its adsorption on the heparin-coated Swan–Ganz 
catheter. Mixtures involving NI were compatible provided that NI was supplied 
in amber syringes or protected with aluminum foil.  
14) Ramanath, Hymavath  (2012)26 performed a observational, prospective 
study  on assessment of intravenous admixtures in hospitalized patients of a 
rural tertiary care teaching hospital. The present study mainly focused on 
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clinical pharmacist assessment in intravenous admixtures administration. 
Drug incompatibility reactions may not only generate a many particles in the 
infusate, but also transform the drug into an inactive form and deleterious 
effects on the patient’s prescribed drug regimen. Drug incompatibility 
reactions are the one of the most common errors in infusion therapy. The 
various clinical effects caused due to incompatibilities ultimately cause tissue 
ischemia, hypoxia and impairment in discharge of metabolic end products. 
This study showed that Clinical Pharmacist assessment in intravenous 
admixture will helps in minimizing of incompatibilities , unidentified area 
research gaps , and also make the nurses to aware about nursing care 
/precautions in intravenous administration.  
15) Kanji  et al (2010)27  conducted a study on systematic review of physical 
and chemical compatibility of commonly used medications administered by 
continuous infusion in intensive care units . The aim of the study is to quantify 
the physical and chemical stability data published for commonly used 
continuously infused medications in the intensive care unit and to evaluate the 
quality of the studies providing these data. The study concluded that physical 
compatibility studies that provide the basis for y-site compatibility are lacking 
for commonly used medications in intensive care unit patients and may 
contribute to unsafe medication practices and also the heterogeneity in the 
methodology of these studies likely contributes to the common finding of 
conflicting data for specific combinations of drugs. 
16) Kalikstad et al (2010)28 performed a study on Compatibility of drug 
infusions in the NICU. The majority of drugs used in sick newborns receiving 
intensive care are unlicensed and off-label, exposing infants to greater risk of 
adverse drug reactions.  Our aim was to study the compatibility of co-infusions 
for a selected group of drugs and nutrition solutions as part of our quality 
assurance programme in the neonatal intensive care unit. The authors 
reviewed drug studies in the literature and t he results of searches were 
reviewed against predetermined criteria for co-infusion of 13 intensive care 
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drugs with 66 other drugs and two nutrition solutions and albumin. Study 
concluded that here is a lack of data on compatibility for the majority of drugs 
used for co-infusions in neonates and therefore caregivers therefore need to 
pay special attention to infusion lines when drugs are co-administer.Their 
results also suggest that further studies on drug compatibility are needed to 
reduce possible ADRs and toxicity, and avoid precipitation and occlusion of 
infusion lines in critically ill neonates.  
17) De Giorgi et al (2010)29 studied on the Evaluation of tools to prevent drug 
incompatibilities in paediatric and neonatal intensive care units. Intravenous 
drug administration in neonatal (NICU) and paediatric intensive care units 
(PICU) is critical because of poor venous access, polymedication, fluid 
restriction and low infusion rate. Risk is further increased by inadequate 
information on the physicochemical compatibility of drugs. Eight decision-
supporting tools were hence evaluated to improve the detection of drug 
incompatibilities in paediatric wards. The percentage of non-compliant 
answers was calculated for both the performing pharmacists and the tools 
.Study concluded that large ranges of pharmacists’ non complaint answers 
shows that such an assessment is subject to different interpretations. 
Standard operating procedures for drug-incompatibility assessment should be 
implemented in drug-information centres.  
18) Knudsen et al (2010)30 conducted a study on Physicochemical 
compatibility of commonly used analgesics and sedatives in the intensive care 
medicine. To minimise the risk of incompatibilities in parenteral drugs in a 
cardiovascular intensive care unit by analysing the physical and chemical 
compatibility of seven commonly used analgesics and sedatives and to 
determine whether these drugs can be administered by the same intravenous 
line. Clonidine hydrochloride, 4-hydroxybutyricacid, (S)-ketamine 
hydrochloride, lormetazepam, midazolam hydrochloride, piritramide and 
sufentanil citrate were diluted with sodium chloride 0.9% to standardised 
concentrations and mixed in different ways and combinations and stored for 7 
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days.During storage physical incompatibility was verified  by visually and the 
chemicalcompatibility of two multiple drug mixtures and 10 drugpairs was 
determined by high-performance liquid chromatography examination. The 
study found that 4-Hydroxybutyric acid was physically incompatible with (S)-
ketamine hydrochloride, midazolamhydrochloride and piritramide .Also the 
combination of clonidine hydrochloride and sufentanil citrate showed 
instabilities within the first hours after mixing. The auhtors concluded that 4-
Hydroxybutyric acid carries a major risk for incompatibilities when mixed with 
other drugs and therefore has to be administered separately. Mixtures of 
clonidine hydrochloride and sufentanil citrate should only be used with great 
caution, and a dose adjustment should be considered. 
19) Newton David (2009)7 performed study on Drug incompatibility chemistry. 
The purpose of the study is to know the chemical interactions that cause drug 
incompatibility in solutions, with emphasis on the acid–base and ionized–
nonionized forms of organic, weak, electrolyte drugs. When the dilution or 
mixing of the salt or ionized forms of organic drugs results in precipitation. 
Acid–base reactions are the most common causes of drug incompatibility as 
precipitation of nonionized drug forms. The authors concluded that 
incompatibility of drug and nutrient injections is clinically hazardous and  
precipitation in injectable drug solutions should be suspected, particularly 
when oppositely charged drug salts are mixed in relatively strong 
concentrations and when pH values of dilutions create more than 1% of 
nonionized drug forms. 
20) Bertsche et al (2008)31 conducted a study on the Prevention of 
Intravenous Drug Incompatibilities in an intensive care unit. The authors 
discussed the frequency of drug administration errors and incompatibilities 
between intravenous drugs before and after an intervention in an intensive 
care unit. They included the most frequent brands of I.V medications used in 
the ICU of a gastroenterological department in retrospective analysis. They 
found out the all possible combinations and resulting incompatibilities. Study 
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stated that administration of incompatible I.V drugs in critically ill patients was 
frequent but can significantly reduced by  following procedural interventions 
with SOP. 
21) Walker et al (2004)32performed a study on Physical Compatibility of 
Pantoprazole with Selected Medications during Simulated Y-Site 
Administration. Patients receiving IV pantoprazole often require concomitant 
IV drugs and solutions. The objective of the study is to complete a visual 
compatibility study of IV pantoprazole with 17 other IV medications, as well as 
with a mixture of 3.3% dextrose and 0.3% sodium chloride for injection, during 
simulated Y-site injection. Seventeen drugs, each at 3 different 
concentrations, as well as a mixture of 3.3% dextrose and 0.3% sodium 
chloride forinjection, were selected for physical compatibility testing with 3 
concentrations (0.16 mg/mL, 0.40 mg/mL, and 0.80 mg/mL) of pantoprazole in 
0.9% sodium chloride for injection (NS).The authors concluded that 
admixtures prepared in the clinical setting are subject to greater error than in 
the laboratory, and it is therefore recommended that practitioners avoid Y-site 
administration of pantoprazole with incompatible drugs. 
22) Trissel, Christopher (2001)33 studied on the topic Incompatibility of 
Lansoprazole Injection with other drugs during stimulated Y site 
Administration. The purpose of the study was to evaluate the physical 
compatibility of lansoprazole injection during stimulated Y site injection with 
112 other drugs by visual observation, turbidity measurement and particle 
content assessment. Of the drugs tested ,92 incompatible with lansoprazole 
0.55mg/ml in 0.9% NaCl injection during the fourth hour observational period. 
The authors concluded that only twenty drugs were found to be physical 
compatible with lansoprazole and ninety two drugs exhibited physical 
incompatibility within 4hours 
23)Gikic et al (2000)14 performed a open prospective study on evaluation of 
physiochemical incompatibilities during parenteral drug administration in a 
pediatric intensive care unit. The objective of the study is to identify 
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prospectively the combinations of injectable drugs administered in the 
paediatric intensive care unit and to analyze them according to the information 
found in literature. The authors concluded that in vitro compatibility tests on 
standard drug combinations as well as a training program for nurses on drug 
incompatibility problems would sensitively increase the security of parenteral 
drug administration 
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SCOPE OF STUDY 
Critically ill patients in the Intensive Care Unit (ICU) require multiple 
medications, often administered as continuous intravenous infusions. Since IV 
access is usually limited, they need to be administered at the same time 
through the same port of a central venous catheter or peripheral venous 
catheter. This is facilitated by a “Y-site” connector that can be joined to a port 
on any catheter. Two or more medications that are administered via Y-site 
connector mix in the lumen of the tubing prior to being infused into the patient. 
However, not all medications can be physically mixed together. The accepted 
standard for medications deemed to be compatible for Y-site co-
administration is that they must be physically compatible, which typically 
means that when mixed, there is no gross evidence of incompatibility at 
clinically relevant concentrations over a period of time. In contrast, when two 
or more medications are intended to be prepared as a mixture and infused 
from the same bag or bottle, they are required to demonstrate chemical 
stability whereby the molecular integrity of all components of the mixture are 
maintained for the duration of mixing. The main difference between the two is 
the duration of mixing that warrants different standards. Medications that are 
combined via Y-site typically mix for less than one minute prior to being 
infused into the patient. Medications that are pre-mixed in the same bag or 
bottle will mix for much longer. When there is a challenge of administering 
more medication infusions than there are ports available, they are forced to 
consider co-administering multiple medications through the same 
port/catheter using a Y-site connector.  
The potential complications of co-administration of incompatible 
medications include precipitation, central venous catheter occlusion requiring 
additional venous access, reduced potency of medication, therapeutic failure 
and local and systemic inflammatory reactions. The prevalence and outcomes 
of these types of complications are not well documented. Previous studies 
found incompatibility problems in upto 18.6% of critical care patients and 
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18.7% of continuously infused medications. Few studies have reported co-
infusion of incompatible medications leading to negative outcomes in humans 
such as pulmonary embolism of medication precipitates. In September of 
2007 the FDA issued an alert related to the co-administration of calcium-
containing products and ceftriaxone due to potential end-organ damage 
associated with calcium-ceftriaxone precipitates leading to lung and kidney 
damage. A subsequent report suggested that the majority of these negative 
outcomes were due to a Y-site incompatibility between ceftriaxone and 
calcium infusions administered simultaneously through the same intravenous 
catheter. Various factors such as solvents, diluents, infusion fluids, pH of each 
drug, duration of stability and concentration of the selected critical care drugs 
play a major role in determining the compatibility of intravenous drug infusions 
at the Y-junction. More than 90% of the drugs are organic, weak electrolytes, 
especially those compounded, manufactured or reconstituted as injections in 
predominantly ionized or salt forms. Acid-base reactions are most common 
causes of drug incompatibility as precipitation of nonionized drug forms. 
Precipitation is likely when oppositely charged, organic drug ions that contain 
aromatic rings are combined in relatively strong concentrations. Salts of 
polyvalent anions and cations are generally less soluble than salts in which 
both ions are monovalent or in which one ion is monovalent and its opposite 
ion is polyvalent. The proposed study l tests the hypothesis that polyvalent 
ions in the co-infused drug solutions or acid-base reactions between the 
continuously infused drug solution and Y-site administered drug would cause 
a significant number of physicochemical incompatibilities in the Medical 
Intensive Care Unit.   
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OBJECTIVE OF THE STUDY 
 To study the influence of polyvalent ions in the co-infused drug 
solutions and acid-base reactions between the continuously infused 
drug solution and Y-site administered drug on the physicochemical 
compatibility of various critical care drugs used in the Medical Intensive 
Care Unit.  
 To identify the most frequent and clinically significant incompatibilities 
of continuous IV infusions of the selected critical care drugs with Y-site 
administered drugs in the MICU settings. 
 To prepare a two dimensional compatibility chart for the most 
commonly used continuous intravenous infusions and Y-site 
administered drugs in MICU. 
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PLAN OF THE STUDY 
  The proposed study entitled “Effect of pH and polyvalent cations on the 
Y-site incompatibility of continuous intravenous infusions of selected critical 
care drugs in the Medical Intensive Care Unit” was planned and carried out as 
given below. 
Phase 1 
 Identification of research problem and scope of the study 
 Preparation of study protocol 
 Obtaining permission from the hospital ethical committee 
 Literature survey 
Phase II 
 Design of structured proforma. 
 Patient selection, inclusion /exclusion criteria. 
 Data retrieval from intensive care unit department. 
 Identication, evaluation and resolving of incompatibilities in intensive 
care unit. 
 Documentation and concurrent feedback to doctor and nurses. 
Phase III 
 Data Analysis 
 Report Submission 
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METHODOLOGY 
Study Site: Medical Intensive Care Unit (MICU) of a 750 bedded 
multispecialty tertiary care teaching hospital. 
Study Design: Prospective observational study. 
Study Duration: 8 months (from February 2015 to September 2016). 
Inclusion Criteria: Patients admitted to the Medical Intensive Care Unit, 
receiving co-infusions of at least two IV drugs or one drugs are included.  
Exclusion Criteria: Patients who receives continuous intravenous infusion of 
drugs but no Y-site drug administration will be excluded. 
Major Outcome measures: The major outcome measure is the compatibility 
between drugs administerd by continuous intravenous infusion and Y-site 
administerd drugs. Secondary outcome measures include the factors 
influencing compatibility of the drugs such as pH or presence of polyvalent 
cations in the drug or diluents. 
Method:. The medication charts of 80 consecutive patients admitted to the 
Intensive Care Unit and treated with continuous intravenous infusions and Y –
Site administered drugs are analyzed. The diluents, infusion fluid, pH, 
duration of stability, the nature and drug concentrations of the selected critical 
care drugs such as vasoactive agents, other cardiovascular drugs, 
analgesics, other drugs and nutrition solutions are recorded and carefully 
evaluated. Drugs given as continuous intravenous infusions are chosen 
because they have longer infusion time and therefore pose the majority of 
compatibility problems when a second drug is administered at the Y-junction. 
Compatibility of the selected critical care drugs when given as 
continuous intravenous infusions are then analyzed against the Y-site 
administered drugs using the 2-dimensional compatibility chart. On observing 
any incompatibility, the possible mechanism such as acid-base reactions due 
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to pH variations of the co-infused drug solutions/ drug and nutrient solutions 
or drug precipitation due to the presence of polyvalent cations such as Ca2+, 
Mg3+ will be identified. The pH, drug, concentration and other physiochemical 
properties of both drug and infusion fluids were also recorded.  
A 2-dimensional compatibility chart was developed indicating the 
compatibility of selected critical care drug infusions with Y-site administered 
drugs commonly used in the Medical Intensive Care Unit is prepared. Trissel’s 
Handbook of Injectable Drugs, Micromedex Healthcare Series,MEDLINE 
databases and manufacturer’s product information are used as the primary 
source of information. Other sources like AHFS drug information or the 
Stabilis Website are also referred 
Outcome of the study: The primary outcome of the study is the identification 
of the factors causing incompatibility of continuous intravenous infusions and 
Y-site administered drugs in the Medical Intensive Care Unit. The proposed 
study will review the compatibility of continuous intravenous infusions of 
certain selected critical care drugs and nutrition solutions against Y-site 
administered drugs with a view to improving the safety of multidrug therapy in 
the Medical Intensive Care Unit. The study will also lead to the development 
of a two dimensional Y-site compatibility for commonly used critical care drugs 
in the intensive care unit. 
The study will also estimate the prevalence of inappropriate co-
administration of continuously infused IV medications, and also identify the 
gaps in the medication compatibility literature that can be addressed by the 
physical incompatibility studies in future. The compatibility chart prepared in 
the study will help as a tool to reduce the incidence of medication errors in 
critically ill patients when exposed to multiple co-infusions. In other words, the 
proposed study will improve the safety of multidrug therapy in the Medical 
Intensive Care Unit. 
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RESULTS 
Data were obtained from 80 consecutive admissions in Medical 
Intensive Care Unit, of which 55 were male patients. The mean age of the 
study population was 54.0625 19.739 (range: 17 to 87). Their mean duration 
of hospitalization was 1.6330±3.0625 (range: 1 to 7days).  Table 1 shows the 
demographic details of these patients. 
Major diagnosis include Diabetes Mellitus (12.5%), Road Traffic 
Accident/Head Injury(12.5%), Chronic Renal Failure(10%), Systemic 
Hypertension (8.75%), Cerebrovascular Accident(7.5%), Chronic Obstructive 
Pulmonary Disorder (5%), Respiratory Disorders (5%), Cancer (5%), 
Poisoning (5%), Subarachnoid haemorrhage (3.75%), Ischaemic Heart 
Disease (3.75%) and others as shown  in Table 2. 
Total number of drugs prescribed in the study subjects was 682 with a 
mean of 8.743±3.680 (range: 2 to 15). The details are presented in table 3. 
Five hundred and fifty four (81.23%) of the prescribed medications were 
administered intravenously (table 4). Of these, 262 (38.4%) were 
administered as continuous Intravenous infusions (table 5) while 292 
(42.81%) were administered using Y-connector (table 6). Most frequently 
prescribed continuous intravenous infusions were Levetiracetam (9.54%), 
Citicoline (9.16%), Midazolam (6.48%), Methyl Prednisolon (6.10%) and 
Fentanyl (5.34%) while drugs such as Ondansetron (18.83%), Pantoprazole 
(17.80%), Piperacillin Sodium+Tazobactum Sodium (10.60%) and Ceftriaxone 
(9.58%) were most commonly administered using Y-connector. 
Table 7 illustrates the compatibility of continuous intravenous infusions 
with Y-site administered drugs.  Of the 600 drug-drug combinations or drug-
diluent combinations evaluated, two hundred and two combinations (33.66%) 
were found to be compatible while 17 (2.83%) combinations were 
incompatible. The compatibility information of 354 (59%) combinations are not 
reported in the literature and 27 combinations were reported as caution           
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(4.5%) Table 8 and 9 shows the details of compatibility particulars of the 
continuous intravenous infusions with the Y-site administered drugs.  
Fentanyl+ Pantoprazole (1.44%), Metronidazole + Pantoprazole (1.44%), 
Levofloxacin+ Piperacillin Na, Tazobactum Na (0.90%), Ringer Lactate+ 
Ceftriaxone (0.72%) and Fluconazole + Pantoprazole (0.72%) constituted the 
maximum number of incompatibility. 
Details such as the diluents used, rate of infusion, duration of 
administration, concentration of reconstituted solution, presence of 
monovalent or polyvalent ions and pH of the drug solutions are given in table 
11. Only one incompatibility was due to the presence of polyvalent cation 
(Ca++) in the combination while most of the drug pairs were found to have 
differing pH values ranging from 2.5 pH (acidic) to 11(basic). A majority of the 
continuous intravenous infusions had a pH value in the acidic range (except 
ondansetron) while that of Y-site administered drugs were found to be in the 
alkaline range. 
The 2-dimensional compatibility chart prepared is shown table 12. This 
chart indicates the compatibility of selected continuous intravenous infusions 
with Y-site administered drugs commonly used in the MICU. 
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TABLE 1: DEMOGRAPHIC DETAILS (n=80) 
Characteristics of patients No of patients 
Total number of  patients 80 
 
Age (years) 
 17 – 37 
 38 – 58 
 39 – 79 
 80 and above 
 
54.0625 19.739 
10 
23 
25 
22 
Gender 
 Male 
 Female 
 
55 
25 
Duration of hospitalization 1.6330±3.0625 
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TABLE 2: CLINICAL CONDITIONS (n=80) 
 
Sl No Diagnosis 
No.of 
Patients 
Percentage 
(%) 
1 Diabetes Mellitus (DM) 10 12.5 
2 
Road Traffic 
Accident/Head 
Injury(RTA) 
10 12.5 
3 Others 9 11.25 
4 
Chronic Renal 
Failure(CRF) 
8 10 
5 
Systemic Hypertension 
(SHT) 
7 8.75 
6 
Cerebro vascular 
Accident 
6 7.5 
7 
Chronic Obstructive 
Pulmonary Disorder 
(COPD) 
4 5 
8 
Respiratory 
Disorders(RD) 
4 5 
9 Myocardial Infarction (MI) 4 5 
10 Cancer 4 5 
11 Poisoning 4 5 
12 
Subarachnoid 
hemorrhage(SAH) 
3 3.75 
13 
Ischaemic Heart Disease 
(IHD) 
3 3.75 
14 Stroke 2 2.5 
15 
Urinary Tract 
Infection(UTI) 
2 2.5 
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TABLE: 3 DRUGS PRESCRIBED (n=682) 
 
Sl No Drugs Prescribed Number 
Percentage 
(%) 
1 Ondansetron 55 68.75 
2 Pantoprazole 52 65 
3 Piperacillin Tazobactum 31 38.75 
4 Ceftriaxone 28 35 
5 Levetiracetam 25 31.25 
6 Citicoline 24 30 
7 Esomeprazole 17 21.25 
8 Midazolam 17 21.25 
9 Methyl Prednisolone 16 64 
10 Fosphenytoin 15 18.75 
11 Clopidogrel Aspirin 14 17.50 
12 Fentanyl 14 17.50 
13 Frusemide 13 16.25 
14 NorAdrenaline 13 16.25 
15 Paracetamol 12 15 
16 Ethohylline Theophylline 12 15 
17 Levofloxacin 11 13.75 
18 Meropenem 10 12.50 
19 Atorvastatin 9 11.25 
20 Piracetam 9 11.25 
21 Nimodipine 9 11.25 
22 Vitamin k 9 11.25 
23 Cerebroprotein hydrosylate 8 10 
24 Mannitol 8 10 
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25 Amikacin 8 10 
26 Linezolid 8 10 
27 Clindamycin 7 10 
28 Ornidazole 7 10 
29 Hydrocortisone 7 10 
30 Dexamethasone 7 10 
31 Sucralfate 6 7.50 
32 Fluconazole 6 7.50 
33 Edaravone 6 7.50 
34 Clinidipine 6 7.50 
35 ImipenemCilastin 6 7.50 
36 Metronidazole 6 7.50 
37 Dopamine 6 7.50 
38 Calcitrol 6 7.50 
39 Ursodeoxycholic acid 6 7.50 
40 Atracurim 6 7.50 
41 Amlodipine 5 6.25 
42 Telmisartan 5 6.25 
43 Insulin 4 5 
44 Rifaxcimin 4 5 
45 Levothyroxine 4 5 
46 Ramosetron 3 3.75 
47 Potassium Chloride 3 3.75 
48 Febuxstat 3 3.75 
49 Ferrous Fumarate 3 3.75 
50 Vasopressin 3 3.75 
51 Torsemide 3 3.75 
52 Enoxparin Sodium 3 3.75 
53 Lacosamide 3 3.75 
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54 Ketorolac 3 3.75 
55 Cefoperazone Sulbactum 3 3.75 
56 Alphacalcidol 3 3.75 
57 Nevivolol 3 3.75 
58 Folic Acid 3 3.75 
59 Hydroxychloroquinine 3 3.75 
60 Prednisolone 3 3.75 
61 Calcium 3 3.75 
62 Aspirin 3 3.75 
63 Methyl Cobalamine 2 2.50 
64 Amiodarime 2 2.50 
65 Isosorbide Mononitrate 2 2.50 
66 Vancomycin 2 2.50 
67 Dobutamine 2 2.50 
68 Clonazepam 2 2.50 
69 CalciumCarbonate 2 2.50 
70 Amphotericin B 2 2.50 
71 Tranexmic Acid 2 2.50 
72 Chymotrypsin ,trypsin 2 2.50 
73 Trimethoprine,sulphamethoxazole 2 2.50 
74 Tramadol 2 2.50 
75 Pralidoxime 1 1.25 
76 Glycopyrolate 1 1.25 
77 Amoxcillin Clavunate 1 1.25 
78 Acetyl Cysteine 1 1.25 
79 Vitamin B 1 1.25 
80 Colisthimate 1 1.25 
81 Digitoxin 1 1.25 
82 Levodopa Carbidopa 1 1.25 
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83 Ascorbic Acid 1 1.25 
84 L Ornthine L Aspartate 1 1.25 
85 Pazofloxacin 1 1.25 
86 Modafinil 1 1.25 
87 Bethanechol Chloride 1 1.25 
88 Oxcarbamazepine 1 1.25 
89 Calcium Gluconate 1 1.25 
90 Azathioprine 1 1.25 
91 Glimipride 1 1.25 
92 Acetazolamide 1 1.25 
93 Hysocyamine 1 1.25 
94 Prazosin 1 1.25 
95 Moxonidine 1 1.25 
96 Sevelamer 1 1.25 
97 Isolazine 1 1.25 
98 Eplerenone 1 1.25 
99 Cilostazol 1 1.25 
100 Clarithromycin 1 1.25 
101 Sodium Bicarbonate 1 1.25 
102 Lactobacillus acidophillus 1 1.25 
103 Pyrazinamide 1 1.25 
104 Isoniazid 1 1.25 
105 Human Isophane 1 1.25 
106 Mycophenolate 1 1.25 
107 Spiranolactone 1 1.25 
108 Atenalol 1 1.25 
109 Rabiprazole 1 1.25 
110 Sorafinib 1 1.25 
111 Trazadone Hcl 1 1.25 
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112 Cobalamine+Pyridoxine+Thiamine 1 1.25 
113 Doxycycline 1 1.25 
114 Oxfloxacin 1 1.25 
115 Acyclovir 1 1.25 
116 Ceftazidime+Tazobactum 1 1.25 
117 Tazobactum+Sulbactum 1 1.25 
118 Human Insulin 1 1.25 
119 Metformin 1 1.25 
120 Ethambutol 1 1.25 
121 Thyroxine 1 1.25 
122 Cefixime,Oxfloxacin 1 1.25 
123 Amantidime 1 1.25 
124 Magesium Sulphate 1 1.25 
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    TABLE 4 : INTRAVENOUS DRUGS PRESCRIBED                            
(n=554) 
 
Sl 
No 
Drugs Prescribed Dose No. 
Percentage    
(%) 
1 Ondansetron 4 mg 55 9.92 
2 Pantoprazole 40mg 52 9.3 
3 Piperacillin +Tazobactum 4.5g 31 5.59 
4 Ceftriaxone 1g 28 5.05 
5 Levetericetam 500mg 25 4.5 
6 Citicoline 4ml 24 4.33 
7 Esomeprazole 40mg 17 3.06 
8 Midazolam 0.5mcg 17 3.06 
9 Methyl Prednisolone 40mg 16 2.88 
10 Fosphenytoin 150mg 15 2.70 
11 Fentanyl 0.5mcg 14 2.52 
12 Frusemide 20mg 13 2.34 
13 Noradrenaline 0.2mg 13 2.34 
14 Etophylline Theophylline 25.3mg+84.7mg 12 2.166 
15 Levofloxacin 500mg 11 1.98 
16 Vancomycin 500mg 11 1.98 
17 Meropenem 500mg 10 1.80 
18 VitamimK 1 amp 9 1.62 
19 Piracetam 60ml 9 1.62 
20 Nimodipine 30mg 9 1.62 
21 Cerebroprotein Hydrosylate 60mg 8 1.44 
22 Mannitol 2.5mg 8 1.44 
23 Amikacin 500mg 8 1.44 
24 Linezolid 600mg 8 1.44 
25 Ornidazole 500mg 7 1.26 
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26 Clindamycin 600mg 7 1.26 
27 Hydrocortisone 100mg 7 1.26 
28 Dexamethasone 20mg 7 1.26 
29 Fluconazole 200mg 6 1.08 
30 Edaravone 30mg 6 1.08 
31 Imipenem Cilastin 500mg 6 1.08 
32 Metronidazole 500mg 6 1.08 
33 Dopamine 5mcg 6 1.08 
34 Atracuirum 10mg 6 1.08 
35 Insulin 10units 4 0.72 
36 Ramosetron 300mcg 3 0.54 
37 Potassium Chloride 2meq/ml 3 0.54 
38 Vasopressin 300mcg 3 0.54 
39 Torsemide 5mg 3 0.54 
40 Enoxparin Sodium 40mg 3 0.54 
41 Lacosamide 100mg 3 0.54 
42 Sulbactum+Cefoperazone 1g 3 0.54 
43 Prednisolone 300mcg 3 0.54 
44 Dobutamine 2.5mcg 2 0.36 
45 Amphotericin B 2mg 2 0.36 
46 Tranexemic Acid 100mg 2 0.36 
47 Tramadol 50mg 2 0.36 
48 Methylcobalamine 
 
2 0.36 
49 Pralidoxime 1g 1 0.18 
50 Omeprazole 20mg 1 0.18 
51 Amoxcillin Clavunate 500mg 1 0.18 
52 Vitamim B 
 
1 0.18 
53 Pazofloxacin 500mg 1 0.18 
54 Clarithromycin 250mg 1 0.18 
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55 Sodium Bicarbonate 2g 1 0.18 
56 Glycopyrolate 2.5mg 1 0.18 
57 Oxfloxacin 400mg 1 0.18 
58 Acyclovir 200mg 1 0.18 
59 Ceftazidime+Tazoactum 2g 1 0.18 
60 Tazobactum+Sulbactum 2g 1 0.18 
61 Cefixime+Oxfloxacin 10mg 1 0.18 
62 L-ornithine,LAspartate 
 
1 0.18 
63 Magnesium Sulphate 1g 1 0.18 
64 Calcium Gluconate 3g 1 0.18 
65 Folic Acid 1mg 1 0.18 
66 Cobalamine+Pyrodoxime+Thyroxine 
 
1 0.18 
67 Colisthimate 2.5mg 1 0.18 
68 Thiamine 
 
1 0.18 
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TABLE 5 : CONTINOUS INTRAVENOUS INFUSIONS PRESCRIBED 
(n=262) 
 
Sl.No Drug Dose Number 
Percentage 
(%) 
1 Levetiracetam 500mg 25 9.54 
2 Citicoline 4ml 24 9.16 
3 Midazolam 0.5mcg 17 6.48 
4 
Methyl 
Prednisoline 40mg 16 
6.10 
5 Fentanyl 0.5mcg 14 5.34 
6 Noradrenaline 0.2mg 13 4.96 
7 Levofloxacin 500mg 11 4.19 
8 Vancomycin 
 
11 4.19 
9 Meropenem 500mg 10 3.81 
10 Piracetam 
 
9 3.43 
11 Nimodipine 30mg 9 3.43 
12 
Cerebroprotein 
hydrosylate 60mg 8 
3.05 
13 Mannitol 2.5mg 8 3.05 
14 Amikacin 500mg 8 3.05 
15 Linezolid 600mg 8 3.05 
16 Ornidazole 500mg 7 2.67 
17 Clindamycin 600mg 7 2.67 
18 Fluconazole 200mg 6 2.29 
19 Edaravone 30mg 6 2.29 
20 Imipenem+Cilastin 500mg 6 2.29 
21 Metronidazole 500mg 6 2.29 
22 Dopamine 5mcg 6 2.29 
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23 Atracurium 10mg 6 2.29 
24 Insulin 40 units 4 1.52 
25 
Potassium 
Chloride 2meq/ml 3 
1.14 
26 Vasopressin 
 
3 1.14 
27 Lacosamide 100mg 3 1.14 
28 Dobutamine 2.5mcg 2 0.76 
29 Amphotericin B 2mg 2 0.76 
30 Pazufloxacin 500mg 1 0.38 
31 Clarithromycin 250mg 1 0.38 
32 Oxfloxacin 400mg 1 0.38 
33 
Lornithine 
Aspartate 
 
1 
0.38 
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TABLE 6: Y SITE ADMINISTERED DRUGS IN INTENSIVE CARE UNIT 
(n=292) 
 
Sl.No 
Y Site Administered 
Drugs 
Dose Number 
Percentage 
(%) 
1 Ondansetron 4mg 55 18.83 
2 Pantoprazole 40mg 52 17.80 
3 
Piperacillin 
Sodium+Tazobactum 
Sodium 
4.5mg 31 10.60 
4 Ceftriaxone 1g 28 9.58 
5 Esomeprazole 40mg 17 5.82 
6 Fosphenytoin 150mg 15 5.13 
7 Frusemide 20mg 13 4.45 
8 Etophylline+Theophylline 
 
12 4.10 
9 VitaminK 
 
9 3.08 
10 Amikacin 500mg 8 2.73 
11 Hydrocortisone 100mg 7 2.39 
12 Dexamethasone 20mg 7 2.39 
13 Ramosetron 300mcg 3 1.02 
14 Torsemide 5mg 3 1.02 
15 Esomeprazole Sodium 40mg 3 1.02 
16 Sulbactum+Cefoperazone 
 
3 1.02 
17 Prednisolone 300mg 3 1.02 
18 Folic Acid 1mg 3 1.02 
19 Tranexmic acid 100mg 2 0.68 
20 Tramadol 50mg 2 0.68 
21 Methyl cobalamine 
 
2 0.68 
22 Pralidoxime 1g 1 0.34 
23 Omeprazole 20mg 1 0.34 
24 Amoxcillin Clavunate 500mg 1 0.34 
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25 Vitamin B 
 
1 0.34 
26 Glycopyrolate 2.5mg 1 0.34 
27 Acyclovir 200mg 1 0.34 
28 Ceftazidime+Tazobactum 2g 1 0.34 
29 Tazobactum+Sulbactum 2g 1 0.34 
30 Cefexime+Oxfloxacin 10mg 1 0.34 
31 Magnesium Sulphate 1g 1 0.34 
32 Calcium Gluconate 3g 1 0.34 
33 Cobalamine,Pyridoxime 
 
1 0.34 
34 Thiamine 5mg 1 0.34 
35 Colistimethate sodium 2.5mg 1 0.34 
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TABLE 7: COMPATIBILITY OF CONTINOUS INTRAVENOUS DRUGS 
WITH Y SITE ADMINISTERED DRUGS (n=600) 
 
S.No Drug combinations Number Percentage (%) 
1 Compatible ( C ) 202 33.66 
2 Incompatible (IC) 17 2.83 
3 Caution 27 4.5 
4 Not tested (NT) 354 59 
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TABLE 8: DETAILS OF COMPATIBILITY OF CONTINOUS INTRAVENOUS 
INFUSIONS DRUGS WITH Y- SITE ADMINISTERED DRUGS (n=552) 
 
Sl 
No 
Continouss 
Intravenous   
Infusion 
Y-Site Drugs Compatibility No 
Percentage 
(%) 
1 Normal Saline Ondansetron NT 13 2.35 
2 Normal Saline Pantoprazole NT 13 2.35 
3 Levetiracetam Pantoprazole NT 12 2.17 
4 Levetiracetam Ondansetron NT 11 1.99 
5 Midazolam Ondansetron C 10 1.81 
6 Midazolam Pantoprazole Caution 10 1.81 
7 Fentanyl Pantoprazole IC 8 1.44 
8 Normal Saline Ceftriaxone NT 8 1.44 
9 Levetiracetam Fosphenytopin NT 8 1.44 
10 Metronidazole 
Piperacillin Na+ 
Tazobactum Na 
C 8 1.44 
11 Metronidazole Torsemide C 8 1.44 
12 Midazolam Esomeprazole IC 8 1.44 
13 Normal Saline 
Piperacillin Na+ 
Tazobactum Na 
NT 7 1.26 
14 Nor adrenaline Ondansetron NT 7 1.26 
15 
Methyl 
Prednisolone 
Pantoprazole NT 7 1.26 
16 Meropenem Pantoprazole IC 7 1.26 
17 Fentanyl Ondansetron C 7 1.26 
18 Nor adrenaline Pantoprazole NT 6 1.08 
19 Midazolam 
Piperacillin 
Sodium+tazobac
tum Sodium 
NT 6 1.08 
20 Levofloxacin Pantoprazole IC 6 1.08 
21 Normal Saline Furosemide NT 6 1.08 
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22 Dopamine Pantoprazole Caution 6 1.08 
23 Levetiracetam Ceftriaxone NT 6 1.08 
24 Metronidazole Hydrocortisone C 6 1.08 
25 Insulin Ondansetron C 5 
 
26 Nor adrenaline 
Piperacillin 
Sodium+tazobac
tum Sodium 
NT 5 0.90 
27 Meropenem Ondansetron Hcl IC 5 0.90 
28 Normal Saline Esomeprazole NT 5 0.90 
29 Levofloxacin 
Piperacillin 
Na+Tazobactum 
Na 
IC 5 0.90 
30 Ringer Lactate Ondansetron NT 5 0.90 
31 Dopamine Ceftriaxone C 5 0.90 
32 Levetiracetam Furosemide NT 5 0.90 
33 Metronidazole Ondansetron C 5 0.90 
34 Fluconazole 
Piperacillin Na + 
Tazobactum Na 
C 5 0.90 
35 Fentanyl Citrate Dexamethasone C 5 
 
36 Imipenem+Cilastin Ondansetron C 4 0.72 
37 Imipenem+Cilastin Pantoprazole C 4 0.72 
38 Fentanyl 
Piperacillin 
Sodium+tazobac
tum Sodium 
C 4 0.72 
39 Ringer Lactate Ceftriaxone IC 4 0.72 
40 Ringer Lactate Pantoprazole C 4 0.72 
41 Fentanyl Ceftriaxone C 4 0.72 
42 Dopamine 
Piperacillin Na+ 
Tazobactum Na 
C 4 0.72 
43 Potassium Chloride Ceftriaxone C 4 0.72 
44 Potassium Chloride Pantoprazole C 4 0.72 
45 Thiamine Ceftriaxone NT 4 0.72 
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46 Thiamine 
Pantoprazole 
Sodium 
NT 4 0.72 
47 Fluconazole Frusemide IC 4 0.72 
48 Midazolam Amikacin SO4 NT 4 0.72 
49 Ornidazole 
Pipercillin Na + 
Tazobactum Na 
NT 4 0.72 
50 Levofloxacin 
Ethophylline+Th
eophylline 
NT 3 0.5 
51 Levofloxacin Ondansetron Hcl C 3 0.54 
52 Normal Saline 
Ethophylline+Th
eophylline 
NT 3 0.54 
53 Levetiracetam Esomeprazole NT 3 0.54 
54 Midazolam Ceftriaxone C 3 0.54 
55 Levetiracetam 
Piperacillin 
Na+Tazobactum 
Na 
NT 3 0.54 
56 Levetiracetam Vitamin K NT 3 0.54 
57 NorAdenaline 
Calcium 
Gluconate 
NT 3 0.54 
58 Levetericetam Dexamethasone NT 3 0.54 
59 Linezolid Fosphenytoin NT 3 0.54 
60 Linezolid Furosemide C 3 0.54 
61 Meropenem 
Ethophylline 
+Theophylline 
NA 3 0.54 
62 Insulin Ceftriaxone Caution 3 0.54 
63 Insulin Pantoprazole C 3 0.54 
64 Atracurium Pantoprazole IC 3 0.54 
65 Insulin Esomeprazole C 2 0.36 
66 Clindamycin Pantoprazole IC 2 0.36 
67 Clindamycin Deriphylline NT 2 0.36 
68 Fentanyl 
Ethophylline+Th
eophylline 
C 2 0.36 
69 Meropenem Esomeprazole NT 2 0.36 
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70 Meropenem Furosemide C 2 0.36 
71 Levofloxacin Esomeprazole NT 2 0.36 
72 Dobutamine Furosemide IC 2 0.36 
73 Normal Saline Hydrocortisone NT 2 0.36 
74 Levofloxacin Torsemide NT 2 0.36 
75 
Methyl 
Prednisolone 
Piperacillin 
Na+Tazobactum 
Na 
C 2 0.36 
76 Dopamine Ondansetron C 2 0.36 
77 Levetiracetam Ketorolac NT 2 0.36 
78 Normal Saline Vitamin K NT 2 0.36 
79 Linezolid Ceftriaxone C 2 0.36 
80 Linezolid Pantoprazole IC 2 0.36 
81 
Sodium 
Bibarbonate 
Htdrocortisone C 2 0.36 
82 
Sodium 
Bibarbonate 
Ondansetron IC 2 0.36 
83 
Sodium 
Bibarbonate 
Pantoprazole Caution 2 0.36 
84 Levofloxacin Hydrocortisone C 2 0.36 
85 Normal Saline Dexamethasone NT 2 0.36 
86 Normal Saline Fosphenytoin NT 2 0.36 
87 Dopamine Torsemide NT 2 0.36 
88 
Methyl 
Prednisolone 
Ceftriaxone C 2 0.36 
89 Linezolid Fosphenytoin NT 2 0.36 
90 Fentanyl Citrate Fosphenytoin NT 2 0.36 
91 Midazolam Fosphenytoin IC 2 0.36 
92 Potassium Chloride Ondansetron C 2 0.36 
93 
Imipenem + 
Cilastin 
Amikacin 
Sulphate 
C 2 0.36 
94 Midazolam Omeprazole IC 2 0.36 
95 Paracetamol Ondansetron C 2 0.36 
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96 Normal Saline 
Cefuperazone + 
Sulbactum 
NT 2 0.36 
97 
Amoxcillin 
Clavunate 
Ondansetron Hcl NT 2 0.36 
98 
Amoxcillin 
Clavunate 
Pantoprazole Na NT 2 0.36 
99 
Methyl 
Prednisolone 
Amikacin 
Sulphate 
C 2 0.36 
100 
Methyl 
Prednisolone 
Ondansetron Caution 2 0.36 
101 Thiamine 
Amikacin 
sulphate 
NT 2 0.36 
102 Thiamine Ondansetron NT 2 0.36 
103 Mannitol Pantoprazole IC 2 0.36 
104 Mannitol Amikacin SO4 C 2 0.36 
105 Mannitol Ondansetron C 2 0.36 
106 Fluconazole Paracetamol NT 2 0.36 
107 Fluconazole Fosphenytoin NT 2 0.36 
108 Dopamine Enoxparin Na NT 2 0.36 
109 Potassium Chloride Enoxparin Na NT 2 0.36 
110 Metronidazole Ceftazidime C 2 0.36 
111 Levofloxacin Ceftriaxone C 2 0.36 
112 Levetiracetam Dexamethasone C 2 0.36 
113 Atracurium Amikacin SO4 C 2 0.36 
114 Atracurium Ondansetron C 2 0.36 
115 Atracurium 
Pipercillin Na + 
Tazobactum Na 
NT 2 0.36 
116 Potassium Chloride Esomeprazole NT 2 0.36 
117 Potassium Chloride Dexamethasone NT 2 0.36% 
118 Imipenem+Cilastin 
Piperacillin 
Na+Tazobactum 
Na 
NT 1 0.18% 
119 Clindamycin Ondansetron C 1 0.18% 
Results 
 
 Effect of pH and Polyvalent Cations on the Y-Site incompatibility of continuous intravenous                51 
critical care drugs  in the medical intensive care unit                                                                                                                    
 
 
 
120 Clindamycin 
Piperacillin 
Sodium+tazobac
tum Sodium 
C 1 0.18% 
121 Midazolam 
Ethophylline+Th
eophylline 
C 1 0.18% 
122 Imipenem+Cilastin Deriphylline NT 1 0.18% 
123 Nor Adrenaline Esomeprazole NT 1 0.18% 
124 Aminophylline Ceftriaxone IN 1 0.18% 
125 Aminophylline 
Enoxparin 
Sodium 
NT 1 0.18% 
126 Aminophylline Hydrocortisone NT 1 0.18% 
127 Aminophylline Pantoprazole C 1 0.18% 
128 Aminophylline 
Ethophylline 
+Theophylline 
NT 1 0.18% 
129 Metronidazole Torsemide C 1 0.18% 
130 Linezolid Ondansetron C 1 0.18% 
131 Linezolid Vitamin K NT 1 0.18% 
132 Normal Saline 
Calcium 
Gluconate 
NT 1 0.18% 
133 Dopamine 
Calcium 
Gluconate 
NT 1 0.18% 
134 Dopamine Esomeprazole IN 1 0.18% 
135 NorAdenaline Esomeprazole NT 1 0.18% 
136 
Sodium 
Bibarbonate 
Piperacillin Na+ 
Tazobactum Na 
C 1 0.18% 
137 Metronidazole Esomeprazole NT 1 0.18% 
138 Dopamine Folic Acid NT 1 0.18% 
139 Dopamine Vitamin K NT 1 0.18% 
140 Nor Adrenaline Folic Acid NT 1 0.18% 
141 Nor Adrenaline Vitamin K NT 1 0.18% 
142 Nor Adrenaline Oxfloxacin NT 1 0.18% 
143 Dopamine Oxfloxacin NT 1 0.18% 
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144 
Methyl 
Prednisolone 
Fosphenytoin NT 1 0.18% 
145 Paracetamol 
Amikacin 
Sulphate 
NT 1 0.18% 
146 Paracetamol Ceftriaxone C 1 0.18% 
147 
Methyl 
Prednisolone 
Enoxparin Na NT 1 0.18% 
148 Normal Saline Enoxparin Na NT 1 0.18% 
149 Metronidazole Vitamin K NT 1 0.18% 
150 Metronidazole 
Theophylline + 
Ethophylline 
NT 1 0.18% 
151 Clarithromycin Hydrocortisone C 1 0.18% 
152 Clarithromycin Ondansetron NT 1 0.18% 
153 Clarithromycin Pantoprazole NT 1 0.18% 
154 Clarithromycin 
Theophylline + 
Ethophylline 
NT 1 0.18% 
155 
Sodium 
Bicarbonate 
Esomeprazole NT 1 0.18% 
156 
Sodium 
Bicarbonate 
Ceftriaxone C 1 0.18% 
157 Clindamycin Ceftriaxone IC 1 0.18% 
158 Clindamycin Esomeprazole NT 1 0.18% 
159 Dobutamine Pantoprazole IC 1 0.18% 
160 Levetiracetam Glycopyrolate NT 1 0.18% 
161 Levetiracetam Pralidoxime NT 1 0.18% 
162 Mannitol Ceftriaxone C 1 0.18% 
163 Fluconazole Amikacin So4 C 1 0.18% 
164 Normal Saline Colisthimate NT 1 0.18% 
165 
Imipenem + 
Cilastin 
Esomeprazole NT 1 0.18% 
166 Paracetamol Esomeprazole NT 1 0.18% 
167 Paracetamol 
Piperacillin Na + 
Tazobactum Na 
C 1 0.18% 
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168 Paracetamol Tramadol NT 1 0.18% 
169 Clindamycin Furosemide C 1 0.18% 
170 
Methyl 
Prednisolone 
Furosemide C 1 0.18% 
171 Normal Saline Ramosetron NT 1 0.18% 
172 Fluconazole Acyclovir C 1 0.18% 
173 Fluconazole Ondansetron C 1 0.18% 
174 Normal Saline Acyclovir NT 1 0.18% 
175 Amphotericin B Acyclovir NT 1 0.18% 
176 Amphotericin B Ondansetron IC 1 0.18% 
177 Amphotericin B Pantoprazole IC 1 0.18% 
178 Nor Adrenaline Dexamethasone NT 1 0.18% 
179 Nor Adrenaline 
Ethophylline+ 
Theophylline 
NT 1 0.18% 
180 Nor Adrenaline Ceftriaxone NT 1 0.18% 
181 Vasopressin Pantoprazole C 1 0.18% 
182 Vasopressin 
Piperacillin Na + 
Tazobactum Na 
C 1 0.18% 
183 Normal Saline Amikacin SO4 NT 1 0.18% 
184 Atracurium Ketorolac NT 1 0.18% 
185 Midazolam Ketorolac NT 1 0.18% 
186 Fentanyl Ketorolac C 1 0.18% 
187 Mannitol 
Pipercillin Na + 
Tazobactum Na 
C 1 0.18% 
188 Vancomycin Ondansetron C 1 0.18% 
189 Vancomycin Pantoprazole Caution 1 0.18% 
190 Vancomycin 
Pipercillin Na + 
Tazobactum Na 
Caution 1 0.18% 
191 Meropenem Paracetamol Caution 1 0.18% 
192 Levofloxacin Oxfloxacin C 1 0.18% 
193 Ringer Lactate Esomeprazole C 1 0.18% 
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194 Ringer Lactate 
Thiamine,Cobala
mine,Pyridoxine 
C 1 0.18% 
195 Ringer Lactate Tranexmic Acid C 1 0.18% 
196 Lacosamide Ceftriaxone NT 1 0.18% 
197 Lacosamide Ondansetron NT 1 0.18% 
198 Lacosamide Pantoprazole NT 1 0.18% 
199 Ringer Lactate Hydrocortisone C 1 0.18% 
200 Ringer Lactate 
Pipercillin Na + 
Tazobactum Na 
Caution 1 0.18% 
201 DNS Pantoprazole C 1 0.18% 
202 DNS Ceftriaxone NT 1 0.18% 
203 DNS 
Pipercillin Na + 
Tazobactum Na 
NT 1 0.18% 
204 Insulin 
Piperacillin 
Sodium+ 
Tazobactum 
Sodium 
C 1 0.18% 
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TABLE 9: COMPATIBILITY OF CONTINOUS INTRAVENOUS INFUSIONS 
WITH SYRINGE PUMP ADMINISTERED DRUGS AT Y-SITE (n=48) 
 
Sl 
No 
Continouss 
Intravenous 
Infusion 
Syringe Pump 
Administerd Drugs 
Compat
ibility 
No. 
Percentage 
(%) 
1 Methyl Prednisolone Midazolam C 3 6.25 
2 Levetiracetam Midazolam NT 3 6.25 
3 NS Fentanyl Citrate NT 3 6.25 
4 Levetiracetam Fentanyl citrate NT 2 4.16 
5 NS Noradrenaline NT 2 4.16 
6 Thiamine Fentanyl citrate NT 2 4.16 
7 Thiamine Midazolam NT 2 4.16 
8 Metronidazole Noradrenaline NT 2 4.16 
9 Ornidazole Dobutamine NT 2 4.16 
10 Ornidazole Dopamine NT 2 4.16 
11 Methyl Prednisolone Atracurium C 1 2.08 
12 Methyl Prednisolone Fentanyl citrate C 1 2.08 
13 Linezolid Atracurium C 1 2.08 
14 Linezolid Fentanyl Citrate C 1 2.08 
15 Linezolid Noradrenaline NA 1 2.08 
16 Linezolid Midazolam C 1 2.08 
17 Levetiracetam Atracurium NT 1 2.08 
18 Insulin Noradrenaline NT 1 2.08 
19 Levofloxacin Noradrenaline NT 1 2.08 
20 Insulin Dopamine C 1 2.08 
21 Levofloxacin Dopamine C 1 2.08 
22 Mannitol Fentanyl citrate C 1 2.08 
23 Mannitol Midazolam C 1 2.08 
24 Meropenam Dobutamine C 1 2.08 
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25 Methyl Prednisolone Dobutamine C 1 2.08 
26 Meropenam Fentanyl citrate NT 1 2.08 
27 Meropenam Midazolam NT 1 2.08 
28 Metronidazole Fentanyl citrate C 1 2.08 
29 Metronidazole Midazolam C 1 2.08 
30 Metronidazole Dopamine C 1 2.08 
31 
Clindamycin 
Phosphate 
Fentanyl citrate C 1 2.08 
32 
Clindamycin 
Phosphate 
Midazolam C 1 2.08 
33 Imipenam+ Cilastin Midazolam IC 1 2.08 
34 Imipenam+ Cilastin Dopamine C 1 2.08 
35 Mannitol Fentanyl citrate C 1 2.08 
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TABLE 10:  COMPATIBILITY OF CO – INFUSIONS ADMINISTERED 
THROUGH Y-SITE (n=65) 
 
Sl 
No 
Infusion 1 Infusion 2 Compatibility No. 
Percentage 
(%) 
1 Midazolam Fentanyl Citrate C 10 15.38 
2 Nor Adrenaline Dopamine NT 6 9.20 
3 Atracurium Fentanyl Citrate C 5 7.69 
4 Normal Saline Ornidazole NT 5 7.69 
5 Normal Saline Levetiracetam NT 4 6.15 
6 Nor Adrenaline Fentanyl Citrate NT 4 6.15 
7 Nor Adrenaline Midazolam NT 3 4.61 
8 Normal Saline Levofloxacin C 2 3.07 
9 Atracurium Midazolam C 2 3.07 
10 
Potassium 
Chloride 
Levetiracetam NT 2 3.07 
11 Levetiracetam Fentanyl Citrate NT 2 3.07 
12 Levofloxacin Insulin IC 2 3.07 
13 Normal Saline Midazolam NT 2 3.07 
14 
Potassium 
Chloride 
Insulin C 2 3.07 
15 Normal Saline Dopamine NT 2 3.07 
16 Normal Saline Noradrenaline NT 2 3.07 
17 Normal Saline Vancomycin NT 1 1.53 
18 Normal Saline Fluconazole NT 1 1.53 
19 Normal Saline Amphotericin B NT 1 1.53 
20 
Potassium 
Chloride 
Dopamine C 1 1.53 
21 Normal Saline Linezolid NT 1 1.53 
2 Dobutamine Fentanyl Citrate C 1 1.53 
23 Dobutamine Midazolam C 1 1.53 
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234 Normal Saline 
Sodium 
Bicarbonate 
NT 1 1.53 
25 Levofloxacin 
Sodium 
Bicarbonate 
C 1 1.53 
26 Dopamine Fentanyl C 1 1.53 
27 Dopamine Midazolam C 1 1.53 
28 Normal Saline 
Imipenem+Cilasti
nq 
NT 1 1.53 
29 Nor Adrenaline 
Sodium 
Bicaronate 
NT 1 1.53 
30 Dopamine 
Sodium 
Bicaronate 
IC 1 1.53 
31 Normal Saline Atracurium NT 1 1.53 
32 Mannitol Midazolam C 1 1.53 
33 Levetiracetam Nimodipine NT 1 1.53 
34 Normal Saline Meropenem NT 1 1.53 
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TABLE 11: DETAILS OF INCOMPATIBLE DRUGS 
 
Drugs given by 
continuous intravenus 
infusion 
Ysite  
administered 
drug & dose 
Dil: of 
Infusion 
Rate of 
infusion 
Duration 
ion of 
infusion 
Conc: of 
reconstit
uted soln 
Diluent of Y- 
site 
administered 
drug 
Presence  of 
Polyvalent 
or 
monovalent 
ions 
pH of 
continuous 
intravenous 
infusion 
pH of 
Ysite 
administer
ed drugs 
Dobutamine 
Frusemide 20 
mg 
- 1.8ml/hr 24hrs - 2ml direct - 2.5-5.5 8-9.3 
Linezolid 
(600mg 
Pantoprazole 
(40mg) 
- 100ml/hr 1hr 4mg/ml 10 ml NS - 
 
2.5-5.5 
9-10 
NaHCO3 
Ondansetron 
(4mg) 
- 50ml/hr 1 hr - 2ml direct Na + 8.4 3.3-4 
Midazolam 
(15mg) 
Fosphenytoin NS 5ml/hr 24hrs 1.5mg/ml 10ml NS Cl- 2.5-3.5 8.3 to 9.3 
Midazolam 
(15mg 
Omeprazole 
(20mg) 
- 100ml/hr 24hrs 2mg/ml 10ml NS Na+ 2.5-3.5  
Midazolam 
(15mg 
Esomeprazole NS 5ml/hr 24hrs 4mg/ml 10ml NS Cl- 2.5-3.5 9-11 
Dobutamine 500mg Pantoprazole NS 1.8ml/hr 24hrs 10mg/ml 10 ml NS - 2.5-5.5 9-10 
Fluconazole 
Furosemide(20
mg) 
- 100ml/hr 1hr 2mg/ml 10 ml NS SO2
- 4 to 8 8-9.3 
RL Ceftriaxone - 50ml/hr 2hr 100mg/ml 10ml SWI Ca++ 6.5 6.6 
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TABLE 12: TWO DIMENSIONAL COMPACTABILITY CHART 
 
 
Ceftriaxo
ne 
Eso
mep
razo
le 
Levofl
oxacin 
Midazo
lam 
Onda
nsetro
n 
Pantop
razole 
Pipera
cillin-
Tazoba
ctum 
Ringer 
Lactate 
Sodiu
m 
Bicarb
onate 
Atracu
rium 
Line
zolid 
Fentany
l 
Metro
nidaz
ole 
Flucana
zole 
Ceftriaxone - NT C C 
Cautio
n 
C NT IC C C C C C Caution 
Esomeprazole NT - NT IC NT NT NT C NT NT NT C NT NT 
Levofloxacin C NT - C C IC IC NI C C C C C C 
Midazolam C IC C - C NT IC C IC C C C C C 
Ondansetron C NT C IC - Caution C C IC C C C C C 
Pantoprazole NT NT C C IC - C C IC IC I I I I 
Piperacillin- 
Tazobactum 
C NT IC Caution IC Caution - C NT NT C C C C 
Ringer Lactate NT NT IC IC C Caution 
Uncerta
in 
- C IC C NI C C 
Sodium 
Bicarbonate 
IC C NI C C C NI 
Caution
- 
- IC C C C C 
Atracurium C NT C C C IC NT IC IC - C C C C 
Linezolid C NT C C C IC C C C C - C C C 
Fentanyl C C C C C IC C NI C C C - C C 
Metronidazole C NT C C C IC C C C C C C - C 
Flucanazole Caution NT C C C IC C C C C C C C - 
 
NT-Not Tested,C-Compatible,IC-
Incompatible 
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DISCUSSION 
 The current study showed that 2.83(%) combinations were 
incompatible. The incompatibility between ceftriaxone and Ringer Lactate was 
due to the presence of polyvalent cation (Ca++) in the diluents. This result is 
supported by the previous work done by Sumeet et al who reported that 
mixing calcium‐containing solutions, including Hartmann’s solution or Ringer’s 
lactate, with ceftriaxone causing the formation of the insoluble ceftriaxone 
calcium salt. Most of the incompatibilities were due to differing pH values of 
the drug pairs or drug and diluents.  A majority of the continuous intravenous 
infusions had a pH value in the acidic range (except ondansetron) while that 
of Y-site administered drugs were found to be in the alkaline range. The water 
solubility of any drug is enhanced by ionisation of the molecule. For a drug 
molecule which acts as a proton acceptor (a Lowry-Bronsted base), ionisation 
is achieved by formulation in a low pH solution usually as a hydrochloride or 
hydrogen sulfate salt (for example, amiodarone hydrochloride or adrenaline 
acid tartrate). Conversely, for a drug molecule which can lose a proton or 
hydrogen ion (a Lowry-Bronsted acid – usually a weak organic acid), 
ionization is achieved by formulation in a high pH solution, usually as a 
sodium or potassium salt (for example, benzylpenicillin sodium). Any change 
in pH towards the other end of the pH scale will reduce the proportion of 
ionised to un-ionised drug in solution and will therefore reduce the water 
solubility of the drug.  
Dobutamine + pantoprazole constitutes 0.18 % usage among the 
continuous intravenous drug along with Y site drugs. This incompatible drug 
combinations  was also reported by a study carried out by Walker et al 34 who 
also reported that mixtures of pantoprazole with dobutamine, esmolol, or 
midazolam were physically incompatible over clinically useful concentration 
ranges. Precipitation occurred with mixtures containing pantoprazole and 
dobutamine. 
Discussion 
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Linezolid + Pantoprazole (0.36%) was found to be a incompatible 
combinations used in the ICU. This    incompatibility results is supported by 
Cayo Lisa (2013)35.  
The combination of sodium bicarbonate + ondansetron prescribed in 
the MICU was found to be incompatible and similar reports are observed in a  
work carried out by Jarosinski et al36 A faint appearance of a cloudy 
precipitate in the intravenous tubing was reported. 
Midazolam + Fosphenytoin (0.36%) is another incompatible 
combination used in MICU.  A work carried out Riggs 37 reported that 
midazolam free base was precipitated upon admixture of midazolam 
hydrochloride and fosphenytoin solutions. Therefore, midazolam 
hydrochloride and fosphenytoin should not be given via the same IV line. 
Dobutamine + Furosemide (0.36%) were found to be incompatible in 
our study. This incompatibility results was consistent with the work carried out 
by Cabezas et al (2015)12. A possible explanation for this instability could be 
related to the fact that furosemide solutions are mildly alkaline and so should 
be stable when mixed with neutral or weakly basic solutions. However, 
combination with dobutamine resulted in an acidic solution of pH 4.8-5 which 
might destabilize furosemide leading to instability to the final mixture. 
Midazolam+esomeprazole combination used in the study site was 
found to be incompatible. This incompatibility results is supported by the work 
carried out by Cabezas et al who reported that Esomeprazole in the mixture 
with midazolam 4 mg/mL and dopamine 8 mg/mL was undetectable, with 
degradation product peaks present on the chromatogram. Other incompatible 
combinations observed in the study such as Midazolam + Omeprazole, 
frusemide + fluconazole are also reported by Machotka et al (2014).  
 
 
Conclusion 
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CONCLUSION 
 The present study demonstrated that the critically ill patients in the 
Medical Intensive Care Unit are receiving 2.83 % of incompatible combination 
of drugs or drugs and diluents. The 2-dimensional compatibility chart prepared 
in the study will be helpful to avoid incompatibility problems arising due to the 
concurrent administration of these drugs as continuous intravenous infusions 
and Y-site administration.  The undocumented combinations are more when 
compared to incompatible, compatible and variable combinations. This study 
showed that physical compatibility studies provide the basis for Y-site 
compatibility for commonly used medications in the Medical Intensive Care 
unit patients for safe usage. Routine drug administration review to identify 
those incompatible drug combination used in Medical Intensive Care Unit is 
strongly recommended to improve the treatment outcome of patients in the 
ICU. 
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FUTURE OUT LOOK 
 Further studies to estimate the incidence of incompatibility problems in 
critically ill patients are needed and also assess the impact of pharmacist in 
order to avoid incompatibility related problems. Due to increased availability of 
number of drug combinations, the knowledge regarding the incompatibilities of 
intravenous drugs should be improved. It is not possible to predict all 
incompatibilities that may arise, hoping that their occurrence can be 
minimized by active participation of clinical pharmacist in the ward rounds, 
clinical review about the possible incompatibilities & by making the nurses 
aware of the incompatibility problems will enhance the patient safety to a 
substantial degree. Much more studies are needed to get informations about 
undocumented combinations. 
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